Cargando…

Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes

Species A rotavirus (RVA) vaccines based on live attenuated viruses are used worldwide in humans. The recent establishment of a reverse genetics system for rotoviruses (RVs) has opened the possibility of engineering chimeric viruses expressing heterologous peptides from other viral or microbial spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Diebold, Ola, Gonzalez, Victoria, Venditti, Luca, Sharp, Colin, Blake, Rosemary A., Tan, Wenfang S., Stevens, Joanne, Caddy, Sarah, Digard, Paul, Borodavka, Alexander, Gaunt, Eleanor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327695/
https://www.ncbi.nlm.nih.gov/pubmed/35758692
http://dx.doi.org/10.1128/jvi.00488-22
_version_ 1784757563742486528
author Diebold, Ola
Gonzalez, Victoria
Venditti, Luca
Sharp, Colin
Blake, Rosemary A.
Tan, Wenfang S.
Stevens, Joanne
Caddy, Sarah
Digard, Paul
Borodavka, Alexander
Gaunt, Eleanor
author_facet Diebold, Ola
Gonzalez, Victoria
Venditti, Luca
Sharp, Colin
Blake, Rosemary A.
Tan, Wenfang S.
Stevens, Joanne
Caddy, Sarah
Digard, Paul
Borodavka, Alexander
Gaunt, Eleanor
author_sort Diebold, Ola
collection PubMed
description Species A rotavirus (RVA) vaccines based on live attenuated viruses are used worldwide in humans. The recent establishment of a reverse genetics system for rotoviruses (RVs) has opened the possibility of engineering chimeric viruses expressing heterologous peptides from other viral or microbial species in order to develop polyvalent vaccines. We tested the feasibility of this concept by two approaches. First, we inserted short SARS-CoV-2 spike peptides into the hypervariable region of the simian RV SA11 strain viral protein (VP) 4. Second, we fused the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, or the shorter receptor binding motif (RBM) nested within the RBD, to the C terminus of nonstructural protein (NSP) 3 of the bovine RV RF strain, with or without an intervening Thosea asigna virus 2A (T2A) peptide. Mutating the hypervariable region of SA11 VP4 impeded viral replication, and for these mutants, no cross-reactivity with spike antibodies was detected. To rescue NSP3 mutants, we established a plasmid-based reverse genetics system for the bovine RV RF strain. Except for the RBD mutant that demonstrated a rescue defect, all NSP3 mutants delivered endpoint infectivity titers and exhibited replication kinetics comparable to that of the wild-type virus. In ELISAs, cell lysates of an NSP3 mutant expressing the RBD peptide showed cross-reactivity with a SARS-CoV-2 RBD antibody. 3D bovine gut enteroids were susceptible to infection by all NSP3 mutants, but cross-reactivity with SARS-CoV-2 RBD antibody was only detected for the RBM mutant. The tolerance of large SARS-CoV-2 peptide insertions at the C terminus of NSP3 in the presence of T2A element highlights the potential of this approach for the development of vaccine vectors targeting multiple enteric pathogens simultaneously. IMPORTANCE We explored the use of rotaviruses (RVs) to express heterologous peptides, using SARS-CoV-2 as an example. Small SARS-CoV-2 peptide insertions (<34 amino acids) into the hypervariable region of the viral protein 4 (VP4) of RV SA11 strain resulted in reduced viral titer and replication, demonstrating a limited tolerance for peptide insertions at this site. To test the RV RF strain for its tolerance for peptide insertions, we constructed a reverse genetics system. NSP3 was C-terminally tagged with SARS-CoV-2 spike peptides of up to 193 amino acids in length. With a T2A-separated 193 amino acid tag on NSP3, there was no significant effect on the viral rescue efficiency, endpoint titer, and replication kinetics. Tagged NSP3 elicited cross-reactivity with SARS-CoV-2 spike antibodies in ELISA. We highlight the potential for development of RV vaccine vectors targeting multiple enteric pathogens simultaneously.
format Online
Article
Text
id pubmed-9327695
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-93276952022-07-28 Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes Diebold, Ola Gonzalez, Victoria Venditti, Luca Sharp, Colin Blake, Rosemary A. Tan, Wenfang S. Stevens, Joanne Caddy, Sarah Digard, Paul Borodavka, Alexander Gaunt, Eleanor J Virol Cellular Response to Infection Species A rotavirus (RVA) vaccines based on live attenuated viruses are used worldwide in humans. The recent establishment of a reverse genetics system for rotoviruses (RVs) has opened the possibility of engineering chimeric viruses expressing heterologous peptides from other viral or microbial species in order to develop polyvalent vaccines. We tested the feasibility of this concept by two approaches. First, we inserted short SARS-CoV-2 spike peptides into the hypervariable region of the simian RV SA11 strain viral protein (VP) 4. Second, we fused the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, or the shorter receptor binding motif (RBM) nested within the RBD, to the C terminus of nonstructural protein (NSP) 3 of the bovine RV RF strain, with or without an intervening Thosea asigna virus 2A (T2A) peptide. Mutating the hypervariable region of SA11 VP4 impeded viral replication, and for these mutants, no cross-reactivity with spike antibodies was detected. To rescue NSP3 mutants, we established a plasmid-based reverse genetics system for the bovine RV RF strain. Except for the RBD mutant that demonstrated a rescue defect, all NSP3 mutants delivered endpoint infectivity titers and exhibited replication kinetics comparable to that of the wild-type virus. In ELISAs, cell lysates of an NSP3 mutant expressing the RBD peptide showed cross-reactivity with a SARS-CoV-2 RBD antibody. 3D bovine gut enteroids were susceptible to infection by all NSP3 mutants, but cross-reactivity with SARS-CoV-2 RBD antibody was only detected for the RBM mutant. The tolerance of large SARS-CoV-2 peptide insertions at the C terminus of NSP3 in the presence of T2A element highlights the potential of this approach for the development of vaccine vectors targeting multiple enteric pathogens simultaneously. IMPORTANCE We explored the use of rotaviruses (RVs) to express heterologous peptides, using SARS-CoV-2 as an example. Small SARS-CoV-2 peptide insertions (<34 amino acids) into the hypervariable region of the viral protein 4 (VP4) of RV SA11 strain resulted in reduced viral titer and replication, demonstrating a limited tolerance for peptide insertions at this site. To test the RV RF strain for its tolerance for peptide insertions, we constructed a reverse genetics system. NSP3 was C-terminally tagged with SARS-CoV-2 spike peptides of up to 193 amino acids in length. With a T2A-separated 193 amino acid tag on NSP3, there was no significant effect on the viral rescue efficiency, endpoint titer, and replication kinetics. Tagged NSP3 elicited cross-reactivity with SARS-CoV-2 spike antibodies in ELISA. We highlight the potential for development of RV vaccine vectors targeting multiple enteric pathogens simultaneously. American Society for Microbiology 2022-06-27 /pmc/articles/PMC9327695/ /pubmed/35758692 http://dx.doi.org/10.1128/jvi.00488-22 Text en Copyright © 2022 American Society for Microbiology. https://doi.org/10.1128/ASMCopyrightv2All Rights Reserved (https://doi.org/10.1128/ASMCopyrightv2) . https://doi.org/10.1128/ASMCopyrightv2This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Cellular Response to Infection
Diebold, Ola
Gonzalez, Victoria
Venditti, Luca
Sharp, Colin
Blake, Rosemary A.
Tan, Wenfang S.
Stevens, Joanne
Caddy, Sarah
Digard, Paul
Borodavka, Alexander
Gaunt, Eleanor
Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes
title Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes
title_full Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes
title_fullStr Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes
title_full_unstemmed Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes
title_short Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes
title_sort using species a rotavirus reverse genetics to engineer chimeric viruses expressing sars-cov-2 spike epitopes
topic Cellular Response to Infection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327695/
https://www.ncbi.nlm.nih.gov/pubmed/35758692
http://dx.doi.org/10.1128/jvi.00488-22
work_keys_str_mv AT dieboldola usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT gonzalezvictoria usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT vendittiluca usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT sharpcolin usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT blakerosemarya usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT tanwenfangs usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT stevensjoanne usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT caddysarah usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT digardpaul usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT borodavkaalexander usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes
AT gaunteleanor usingspeciesarotavirusreversegeneticstoengineerchimericvirusesexpressingsarscov2spikeepitopes